Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 81.25% | -1,270.89% | 88.91% | -78.37% | 51.34% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.28% | -33.41% | 17.37% | 306.56% | -220.05% |
| Change in Net Operating Assets | -331.26% | 149.56% | -147.50% | 218.23% | 20.93% |
| Cash from Operations | 96.55% | -987.49% | 137.13% | 62.64% | 30.23% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.44% | -137.83% | 242.96% | -581.63% | 63.89% |
| Cash from Investing | 97.44% | -67.66% | 67.74% | -581.63% | 63.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 25.74% | 99.25% | -25,098.79% | 4.21% | -1.55% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 28.06% | -102.68% | 7,436.85% | 6.70% | -0.81% |
| Foreign Exchange rate Adjustments | -104.07% | 207.03% | -562.87% | -131.98% | 739.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -200.00% |
| Net Change in Cash | 92.24% | -189.46% | 339.45% | 47.61% | 37.87% |
